

THE NEW AGE FAMILY HOSPITAL



10th November, 2023

To

BSE Limited Corporate Relationship Department P J Towers Dalal Street, Fort Mumbai - 400 001.

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 10th November, 2023

This is to inform you that the Board of Directors at their meeting held today, the 10th November, 2023 approved the Standalone Unaudited Financial results for the Quarter and half year ended 30th September, 2023 along with the Limited Review Report of the Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 12:35 PM and concluded at

12:45 PM.

Thank You

With regards,

For KMC SPECIALITY HOSPITALS (INDIA) LIMITED

Dr Manivannan **Managing Director**

DIN: 00910804





Regd. Office:

KMC Speciality Hospitals (India) Ltd

CIN - L85110TN1982PLC009781

No. 6, Royal Road, Cantonment, Trichy - 620 001.

T 0431 - 4077777 **F** 0431 - 2415402

E info@kauveryhospital.com W www.kauveryhospital.com

Deloitte Haskins & Sells

Chartered Accountants ASV N Ramana Tower, 52, Venkatnarayana Road, T. Nagar, Chennai - 600 017, Tamil Nadu, India

Phone: +91 44 6688 5000 Fax: +91 44 6688 5400

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED FINANCIAL RESULTS

TO
THE BOARD OF DIRECTORS OF
KMC SPECIALITY HOSPITALS (INDIA) LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMC Speciality Hospitals (India) Limited** (the "Company"), for the quarter and half-year ended September 30, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deloitte Haskins & Sells

Chartered Accountants (Firm's Registration No. 008072S)

Sumit Trivedi

(Partner)

(Membership No. 209354) (UDIN: 23209354BGXTFI4270)

HASKINS

CHENNA.

Place: Chennai Date: November 10, 2023 KMC/ST/RB/PB/Q2 2023-24

Statement of unaudited financial results for the quarter and half-year ended September 30, 2023

(Rs. In Lakhs except EPS) **Particulars** Quarter ended Half-year ended Year ended March 31, September 30, September September September 30, June 30, 2023 2023 30, 2022 30, 2023 2022 2023 (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) 1 Income a) Revenue from operations 4,231.98 4,084.32 3,959.55 8,316.30 7,464.81 15,575.64 57.22 77.15 221.23 147.83 312.86 164.01 b) Other income Total income 4,289.20 4,248.33 4,036.70 8,537.53 7,612.64 15,888.50 2 Expenses 288 28 79.87 68.24 166.45 133.82 a) Cost of materials consumed 86.58 b) Purchase of stock-in-trade 519.52 484.91 571.87 1,004.43 1,037.10 2,039.92 20.13 (53.10)c) Changes in inventories of stock-in-trade 0.72 (50.63)20.85 (31.31)3,120,45 879.62 770.56 1.812.58 1.496.63 d) Employee benefits expense 932.96 e) Finance costs 21.45 20.84 14.82 42,29 29.74 81,10 218,91 214.53 183.31 433.44 355,53 764.22 f) Depreciation and amortisation expense g) Other expenses 1,640,94 1,551.97 1,544.78 3,192.91 2,860.56 6,026.81 5.860.28 12.289.47 Total expenses 3,361.03 3,311.92 3.102.95 6,672.95 1,752.36 3,599.03 3 Profit before tax (1-2) 928.17 936.41 933.75 1,864.58 4 Income Tax expense a) Current tax 248,22 258.21 250.99 506.43 479.72 1,003.14 (7.00)(15.44)(18.55)(22.44)(39.56)(72.95)b) Deferred tax 440.16 Total income tax expense 241.22 242.77 232.44 483.99 930.19 701.31 1,380.59 1,312.20 2,668.84 5 Profit for the period (3-4) 686.95 693.64 6 Other comprehensive income / (loss) Items that will not be reclassified subsequently to statement of profit or loss (a) Re-measurement of defined benefit liability (19.01)4.97 (19.37)(1.24)1,42 (0.36)(0.30)0.31 (b) Income tax relating to items that will not be 4.79 0.09 (1.25)4.88 reclassified to statement of profit or loss (14.22)(0.27)3.72 (14.49)(0.93)1.06 Total other comprehensive income / (loss), (net of tax) 7 Total comprehensive income (5+6) 672,73 693.37 705.03 1,366.10 1,311.27 2,669.90 1,630.85 1,630.85 1.630.85 1,630.85 1,630,85 8 Paid-up equity share capital (Face value of 1,630.85 Re.1/- each) 9,719.36 9 Reserves I.e. Other equity 10 Earnings per share (EPS) of Re. 1/- each : 0.42 0.43 0.43 0.85 0.80 1.64 Basic 0.85 0.80 1.64 0.43 0.43 Diluted 0.42 (Not (Not (Not (Not (Not (Annualised) annualised) annualised) annualised) annualised) annualised)





Statement of assets and liabilities

	Particulars	As at	(Rs. In Lakh: As at
	Falticulats	September 30,	March 31,
		2023	2023
		(Unaudited)	(Audited)
Α	Assets		
	Non-current assets		
	Property, plant and equipment	7,741.59	7,835.€
	Right-of-use-assets	350.27	512.6
•	Capital work-in-progress	5,086.70	3,403.7
	Investment property	40,43	40.4
	Other intangible assets	21.32	38.
(1)	Financial assets	0.00	•
	(i) Investments	0.38	0.
	(ii) Other financial assets	390.69 93.93	177.
3)		79.05	66. 155.
	Income tax assets (net) Other non-current assets	1,895.96	748.
I)	Sub-total - Non-current assets	15.700.32	12,979.
	Sub-total - Non-content assets	10,700.02	12,070.
	Current assets		
	Inventories	217.18	227.
1)	Financial assets		
	(i) Trade receivables	532,62	437.
	(ii) Cash and cash equivalents	305.27	183
	(iii) Other bank balances	3,282.00	3,695
	(iv) Loans	21.71 537,97	17 441
	(v) Other financial assets	169.72	183
3)	Other current assets	5,066.47	5,185
	Sub-total - Current assets	5,066,47	5,165.
	Total - Assets	20,766.79	18,165.
	Equity and liabilities		
Ш	Equity		
1)	Equity share capital	1,630,85	1,630.
)	Other equity	11,085.46	9,719
	Sub-total - Equity	12,716.31	11,350
2	Non-current liabilities		
	Financial Liabilitles		
	(i) Borrowings	4,988,87	3,986
- 1.1	(ia) Lease liabilities	266,13	456
	Provisions	77,49	109
	Other non-current liabilities	8.56	8
- 1	Sub-total - Non-current liabilities	5,341.05	4,560
- 11	Current liabilities		
Ί.	Financial liabilities		
	Borrowings	001.00	400
	(i) Borrowings	861.20 102.05	463 88
	(ia) Lease liabilities	102,05	00.
	(ii) Trade payables (A) Total outstanding dues of micro and small	6.91	4.
	(A) Total outstanding dues of micro and small	0,91	٠,
	enterprises	682,26	637.
	(B) Total outstanding dues of creditors other	082,20	037
	than micro and small enterprises	468.34	456
- 1	Other financial liabilities	279.25	315
	Other current liabilities	309.42	288.
	Provisions Sub⊰otal - Current ilabilities	2,709.43	2,254.
	aunaciai - Cuitetti tiautities	2,703.43	4,204.
-1	Total - Equity and liabilities	20,766.79	18,165.





Statement of unaudited condensed cashflow statement for half-year ended September 30, 2023

(Rs. In Lakhs)

ins.				
	Particulars	For the half-year ended September 30, 2023 (Unaudited)	For the half-year ended September 30, 2022 (Unaudited)	
Α	Cash flows from operating activities			
	Profit before tax	1,864.58	1,752.36	
	Operating profit before working capital changes	2,213.41	2,102.44	
	Cash flow from operating activities	1,581.85	1,340.10	
В	Cash flow used in Investing activities	(2,752.97)	(2,343.06)	
С	Cash flow from financing activities	1,292.68	905.53	
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	121.56	(97.43)	
	Cash and cash equivalents at the beginning of the period	183.71	166.68	
	Cash and cash equivalents at the end of the period	305.27	69.25	
	Components of cash and cash equivalents			
	Cash on hand	16.86	14.50	
	Balances with banks			
	- on current accounts	288.41	54.75	
	Total cash and cash equivalents	305.27	69.25	





Notes:

- 1 The above unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and SEBI Circular dated July 5, 2016.
- 2 The above unaudited financial results for the quarter and half year ended September 30, 2023 in respect of KMC Speciality Hospitals (India) Limited ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their Meeting held on November 10, 2023. The above results for quarter and half year ended September 30, 2023 has also been subject to limited review by the Statutory Auditors of the Company.
- 3 The Company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under IND AS 108 Operating Segments.
- 4 The Code on Wages 2019 and Code on Social Security 2020 " the Codes " relating to employee compensation and post-employment benefits received presidential Assent in September 2020 and the Code has been published in the official Gazette. However, the date on which the Code will come into the effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.

Aospila/

Trichy

Place: Chennai

Date: November 10, 2023

HASKINS

for and on behalf of the board of directors of KMC Speciality Hospitals (India) Limited CIN/L85110TN 1082PLC009781

> Dr. S. Manivannan Managing Director DIN: 00910804